Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572581 | 0.83 | ALDH1A1 (0.32) | — | |
| SCHEMBL7069360 | 0.83 | — | — | |
| SCHEMBL7552606 | 0.80 | — | — | |
| SCHEMBL2714868 | 0.69 | KMT2A (0.32) | — | |
| SCHEMBL4954859 | 0.68 | — | — | |
| SCHEMBL6688284 | 0.67 | POLB (0.38) | — | |
| SCHEMBL77388 | 0.67 | POLB (0.33) | — | |
| SCHEMBL4592132 | 0.67 | — | — | |
| SCHEMBL12059192 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL4954865 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642383-B2 | Of the class 3,3,5,5-tetramethyl-2-oxo-1,4-piperazine, polymers thereof; stabilizers for thermoplastic organic polymers, coating compositions or photographic materials | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-11-04 | — | — | US | disclosed |
| US-20020115859-A1 | Oxopiperazinyl derivatives and light stabilized compositions | LAZZARI DARIO (IT) | 2002-08-22 | — | — | US | disclosed |
| US-4477665-A | POLYMER LIGHT AND OXIDATION STABILIZERS | THE B. F. GOODRICH COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0001559-B1 | SYNTHESIS OF 2-KETO-1,4-DIAZACYCLOALKANES | The B.F. GOODRICH Company (US) | 1982-01-13 | — | — | EP | disclosed |
| EP-0024337-A1 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4167512-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| EP-0001559-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115859-A1 | Oxopiperazinyl derivatives and light stabilized compositions | CBR1, PYM1, CCT4 | AR 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.